PepGen Inc
Research PepGen Inc (PEPG) on Bullrun: market cap USD 237.21M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPEPG
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 237.21M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 17.81M
- Free cash flow-USD 15.84M
Valuation Snapshot
latest market cap is USD 237.21M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 89.66M | -USD 81.90M | n/a | -2.12 | USD 60.51M | USD 17.00M | USD 147.44M |
| FY2024 | USD 0 | -USD 89.98M | -USD 82.87M | n/a | -2.85 | USD 49.42M | USD 18.66M | USD 118.62M |
| FY2023 | n/a | -USD 78.63M | -USD 71.60M | n/a | -3.3 | USD 80.77M | USD 20.10M | USD 108.42M |
| FY2022 | n/a | -USD 69.10M | -USD 63.02M | n/a | -4.42 | USD 181.75M | n/a | USD 179.63M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 237.21M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 448.38M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 123.63M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 161.93M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 315.96M | n/a | n/a | n/a |
About PepGen Inc
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PepGen Inc's market cap?
PepGen Inc's market capitalization is USD 237.21M.
What does PepGen Inc do?
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.